Opus Genetics (IRD) Free Cash Flow (2010 - 2026)
Opus Genetics (IRD) reported Free Cash Flow of -$12.7 million for Q1 2026, down 41.51% year-over-year from -$21.8 million in Q1 2025, and down 29.43% quarter-over-quarter from -$9.8 million in Q4 2025.
Opus Genetics (IRD) Free Cash Flow (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Free Cash Flow data on file, last reported at -$12.7 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$12.7 million, down 41.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$39.0 million (down 35.11% YoY), and the FY2025 annual result was -$35.3 million, down 37.84% from the prior year.
- Free Cash Flow eased to -$12.7 million in Q1 2026 per IRD's latest filing, from -$9.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $28.8 million in Q4 2022 and troughed at -$12.7 million in Q1 2026.
- A 5-year average of -$3.6 million and a median of -$5.7 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 609.94% in 2022, then sank 837.31% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $28.8 million in 2022, then plunged by 84.2% to $4.5 million in 2023, then sank by 263.54% to -$7.4 million in 2024, then tumbled by 32.2% to -$9.8 million in 2025, then retreated by 29.43% to -$12.7 million in 2026.
- Business Quant data shows IRD's Free Cash Flow at -$12.7 million in Q1 2026, -$9.8 million in Q4 2025, and -$6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.73 Mn |
| Mar 31, 2026 | -12.73 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Dec 31, 2023 | 4.55 Mn |